PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions. Transcend will operate as a wholly owned subsidiary of Otsuka America, In
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments
